Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 78, Issue 1, Pages 32-39Publisher
CARDEN JENNINGS PUBL CO LTD
DOI: 10.1007/BF02983237
Keywords
arsenic trioxide; acute promyelocytic leukemia; hematologic malignancy; clinical trials; mechanisms of action
Categories
Ask authors/readers for more resources
Acute promyelocytic leukemia (APL) is now the most potentially curable subtype of acute myeloid leukemia in adults because of the introduction of novel approaches in the management of this disease. All-trans-retinoic acid (ATRA)-based therapy is now the first-choice treatment of patients presenting with de novo APL, and clinical studies have shown that nearly all patients who receive ATRA therapy achieve complete remission. However, approximately 20% to 30% of APL patients eventually have relapses with resistance to further ATRA treatment. Arsenic trioxide (As2O3 [ATO]) has been established as highly effective therapy for patients with APL, even for those with disease refractory to ATRA. Furthermore, results of recent studies have suggested a broad therapeutic potential for ATO in the treatment of hematologic malignancies beyond APL. In this review, we discuss the clinical activity and multiple mechanisms of ATO therapy in the management of APL and other hematologic neoplasms. (C) 2003 The Japanese Society of Hematology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available